Vanguard Global Advisers
CORT icon

Vanguard Global Advisers’s Corcept Therapeutics CORT Stock Holding History

Vanguard Global Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Sell
37,417
-547
-1% -$33K ﹤0.01% 969
2026
Q1 		$1.53M Buy
+37,964
New +$1.42M ﹤0.01% 1378

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's CORT Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Corcept Therapeutics (CORT) stake by 1.4% in Q2 2026, selling an estimated $33K and leaving 37,417 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #969.

Vanguard Global Advisers first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 415 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Vanguard Global Advisers held 37,417 shares of Corcept Therapeutics worth $3.25M as of Q2 2026.
  • Vanguard Global Advisers sold 547 Corcept Therapeutics shares in Q2 2026, an estimated $33K.
  • Corcept Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #969 holding.
  • Vanguard Global Advisers first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 415 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.